Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

ACS Pharmacology & Translational Science, Journal Year: 2024, Volume and Issue: 7(4), P. 967 - 990

Published: March 19, 2024

Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized effective disease management. Identification key driver mutations molecular profiling have deepened our comprehension genetic alterations in cancer, facilitating targeted therapy immunotherapy selection. Biomarkers such as microsatellite instability (MSI) DNA mismatch repair deficiency (dMMR) guide decisions, opening avenues for immunotherapy. Emerging liquid biopsies, artificial intelligence, machine learning promise to revolutionize early detection, monitoring, selection precision medicine. Despite these advancements, ethical regulatory challenges, including equitable access data privacy, emphasize importance responsible implementation. The dynamic nature with its tumor heterogeneity clonal evolution, underscores necessity adaptive strategies. future lies potential enhance patient care, clinical outcomes, understanding this intricate disease, marked by ongoing evolution field. current reviews focus on providing in-depth knowledge various diverse approaches utilized against at both biochemical levels.

Language: Английский

---

Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis

Cytokine & Growth Factor Reviews, Journal Year: 2024, Volume and Issue: 79, P. 29 - 38

Published: Aug. 24, 2024

Language: Английский

---

The role and application of Coronin family in human tumorigenesis and immunomodulation

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189304 - 189304

Published: March 1, 2025

Language: Английский

---

Molecular and phenotypic characterization of 5-FU resistant colorectal cancer cells: toward enrichment of cancer stem cells

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 18, 2025

Abstract Cancer stem cells (CSCs) as a subgroup of within tumor capable self-renewal, thereby driving initiation and spread. Addressing treatment failures in cancer, linked to CSCs their resistance mechanisms, requires effective preclinical models for testing targeted therapies. Caco2- HT-29-resistant were generated by repeated with growing concentrations 5-fluorouracil (5-FU) anticancer drug an extended time. The sensitivity 5-FU-resistant was evaluated cytotoxicity assay. Stemness, epithelial-mesenchymal transition (EMT), migration characteristics assessed through gene expression investigation real-time PCR. CD44, CD133, CD66 flow cytometry. To end, the bioinformatic analysis estimated molecular function biological pathways considering differential selected genes proteins. 5-FU-exposed displayed increased 5-FU. showed upregulation stemness ( KLF4 , SOX2 OCT4 C-MYC ), enhanced scavenging system, elevated CSC surface markers (CD44 CD133) compared parental cells. Additionally, pro-EMT TWIST1 SNAIL1 ZEB1 Vimentin N-cadherin ) significantly upregulated cells, downregulation E-cadherin EMT suppressor reflected capacity. Moreover, ABC transporter ABCB1 ABCC1 observed, correlating resistance. highlighted related microRNAs pluripotency, proteoglycans. Methods exposure take priority over spheroid formation, particularly due efficacy stemness, EMT, markers. This positions them promising protocol establishing experimental CSCs.

Language: Английский

---

Expediting the development of robust 5-FU-resistant colorectal cancer models using innovative combined in vivo and in vitro strategies

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 180, P. 117576 - 117576

Published: Oct. 23, 2024

Language: Английский

---